A breakthrough in malaria treatment is on the horizon with the development of a new polymeric prodrug that significantly improves the therapeutic efficacy of tafenoquine. This single-dose prodrug, administered subcutaneously, targets the liver to eliminate the dormant parasite stage and prevent relapses. Notably, the prodrug exhibits reduced hemolysis, making it potentially safe for individuals with glucose-6-phosphate dehydrogenase deficiency, a common enzyme defect that limits the use of current malaria treatments. This development holds promise for mass eradication campaigns, particularly in remote and resource-limited areas where malaria remains a major public health threat.